Telesis Bio (TBIO) AI Stock Analysis

• Market Cap: $1.60M
• Dividend Yield: N/A
• Average Volume (3M): 8.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -54.89%
• EPS Growth: -19.78%
• Country: US
• Employees: 39
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Devices
• EPS (TTM): -28.19
• Shares Outstanding: 1,775,839
• 10 Day Avg. Volume: 6,763
• 30 Day Avg. Volume: 8,117
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.05
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 31.01
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 2.92
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Telesis Bio's overall score reflects significant financial challenges, negative valuation metrics, and weak technical indicators. The lack of earnings call data for guidance further limits the visibility of future performance. These factors combined result in a low overall stock score, emphasizing the need for careful consideration by potential investors.

Telesis Bio Business Overview & Revenue Model

Company Description

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

How the Company Makes Money

Telesis Bio makes money primarily through the sale of its DNA synthesis technologies and related services. The company's revenue streams include sales of its proprietary synthetic biology platforms that allow customers to design and synthesize DNA sequences. Telesis Bio also generates income through licensing agreements and collaborations with other biotech firms, research institutions, and pharmaceutical companies. These partnerships often involve the co-development of new products or technologies, which can lead to additional revenue from licensing fees and royalties. Additionally, Telesis Bio may offer contract research services, providing custom DNA synthesis and related solutions to its clients.

Telesis Bio Financial Statement Overview

Summary

Telesis Bio is facing significant financial challenges, including ongoing losses, high leverage, and negative cash flow. The income statement shows consistent net losses and declining revenue. The balance sheet reveals high debt levels and low equity, indicating a precarious financial position. Cash flow inefficiencies further emphasize the operational challenges.

Income Statement

Telesis Bio's financial performance shows significant challenges, with consistent net losses and negative EBIT and EBITDA margins. The company experienced a notable decline in revenue in the TTM period compared to the previous year-end. The gross profit margin is positive, but overall profitability is weak, reflecting high operational costs relative to revenue.

Balance Sheet

The balance sheet highlights a precarious financial position with low stockholders' equity and high debt-to-equity ratios, indicating heavy reliance on debt financing. The equity ratio is low, suggesting limited asset backing by equity. The company needs to manage its liabilities to avoid financial distress.

Cash Flow

Cash flow analysis reveals negative operating cash flow, indicating operational inefficiencies. There are improvements in free cash flow year-over-year, but it remains negative. The free cash flow to net income ratio is unfavorable, reflecting challenges in generating cash from operations.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
27.51M	27.43M	11.04M	6.58M	4.80M
	Gross Profit
16.95M	15.60M	4.30M	3.63M	-4.08M
	EBIT
-46.54M	-46.48M	-35.37M	-16.36M	-6.98M
	EBITDA
-40.49M	-43.62M	-36.00M	-15.49M	-6.12M
	Net Income Common Stockholders
-47.72M	-48.47M	-38.96M	-18.01M	-8.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.16M	43.75M	82.81M	13.46M	29.14M
	Total Assets
70.41M	81.36M	116.26M	26.86M	38.76M
	Total Debt
34.38M	21.43M	17.32M	8.33M	4.77M
	Net Debt
32.81M	-8.99M	-65.48M	-5.14M	-24.38M
	Total Liabilities
40.87M	34.80M	25.47M	52.32M	46.26M
	Stockholders Equity
29.54M	-113.74M	90.78M	-25.46M	-7.50M
Cash Flow		Free Cash Flow
-36.65M	-43.18M	-38.55M	-15.59M	-6.47M
	Operating Cash Flow
-34.67M	-38.72M	-36.70M	-15.38M	-6.39M
	Investing Cash Flow
-5.74M	-18.01M	-15.04M	-204.00K	-79.00K
	Financing Cash Flow
11.56M	4.51M	121.08M	-96.00K	35.11M

Telesis Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TBIO, the sentiment is Positive. The current price of 0.9 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.47, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of 0.15 indicates Negative momentum. The RSI at 61.22 is Neutral, neither overbought nor oversold. The STOCH value of 59.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TBIO.

Telesis Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.32B	3.41	-40.36%	2.89%	17.93%	2.52%
VVOS	46 Neutral	$15.49M	―	-266.25%	―	8.91%	70.18%
TIVC	46 Neutral	$4.42M	―	-184.96%	―	-33.67%	91.72%
PAVM	40 Underperform	$12.99M	―	-499.57%	―	22.15%	―
NAYA	39 Underperform	$1.47M	―	123.97%	―	390.03%	84.00%
TBIO	36 Underperform	$1.60M	―	-175.00%	―	-54.89%	-19.78%

Telesis Bio Corporate Events

Telesis Bio Announces Departure of Chief Legal Officer

Telesis Bio Inc. announces the departure of Chief Legal Officer Robert H. Cutler on October 31, 2024, with a comprehensive severance package including $307,500 and nine months of COBRA premiums, contingent on the company’s financial milestones. Cutler will aid in his role transition through a consulting agreement.